Skip to main content

Table 1 Baseline patient characteristics

From: Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease

Characteristic Aliskiren + ARB Group ARB Group P value
  N = 57 N = 132  
Demographic    
 Age 63.9 ± 19.3 66.5 ± 15.4 0.367
 Male gender 61.4% (n = 35) 68.9% (n = 91) 0.313
Clinical    
 Body-mass index 24.8 ± 3.9 25.2 ± 3.7 0.548
 Mean sitting blood pressure-mmHg    
  Systolic 134.9 ± 16.6 131.0 ± 14.0 0.123
  Diastolic 77.2 ± 10.8 77.4 ± 10.5 0.135
 Urine protein-to-creatinine ratio 1.84 (0.89  2.77) 1.81 (0.84  2.78) 0.723
 Estimated glomerular filtration rate ml/min/1.73 m2 50.9 ± 31.1 42.5 ± 19.9 0.062
 Hemoglobin (g/liter) 12.0 ± 1.9 11.8 ± 1.9 0.525
 Chronic kidney disease stage    0.173
  Stage I 10.5% (n = 6) 4.5% (n = 6)  
  Stage II 17.5% (n = 10) 7.6% (n = 10)  
  Stage IIIA 14.0% (n = 8) 23.5% (n = 31)  
  Stage IIIB 28.1% (n = 16) 36.4% (n = 48)  
  Stage IV 29.8% (n = 17) 28.0% (n = 37)  
Etiology    0.917
 Hypertensive nephropathy 36.8% (n = 21) 34.1% (n = 45)  
 Chronic glomerulonephritis 43.9% (n = 25) 47.0% (n = 62)  
 Interstitial nephritis 19.3% (n = 11) 18.9% (n = 25)  
 Triglycerides (mg/dl) 146.3 ± 100.2 133.0 ± 79.4 0.369
 Cholesterol (mg/dl)    
  Total 198.9 ± 52.4 183.7 ± 45.7 0.062
 Low-density lipoprotein 116.4 ± 38.8 112.4 ± 37.7 0.567
 High-density lipoprotein 51.8 ± 14.0 48.6 ± 17.3 0.309
 Serum potassium (mmol/liter) 4.2 ± 0.5 4.4 ± 0.6 0.037
Antihypertensive drugs received at baseline    
 Calcium-channel blocker 52.6% (n = 30) 43.9% (n = 58) 0.272
 Beta-blocker 21.1% (n = 12) 15.9% (n = 21) 0.393
 Diuretic 35.1% (n = 20) 47.0% (n = 62) 0.130
 Alpha-blocker 14.0% (n = 8) 5.3% (n = 7) 0.042